Indeed, the combination of AFP and CRP in ICI outcome prediction in HCC is rational at the mechanism level; CRP, an acute-phase protein, is a widely-recognized systemic marker of inflammation induced by cancer, and inflammation can contribute to tumorigenesis and disease progression [110, 111]. Here, AFP is linked to hepatocellular carcinoma.